Talk:Sargramostim

note

Another potential use for Leukine:

"A signaling protein released during rheumatoid arthritis dramatically reduced Alzheimer's disease pathology and reversed the memory impairment of mice bred to develop symptoms of the neurodegenerative disease, a new study by the University of South Florida reports. Researchers found that the protein, GM-CSF, likely stimulates the body's natural scavenger cells to attack and remove Alzheimer's amyloid deposits in the brain. . . .

"Moreover, the recombinant human form of GM-CSF (Leukine®) is already approved by the FDA and has been used for years to treat certain cancer patients who need to generate more immune cells," Dr. Potter said. "Our study, along with the drug's track record for safety, suggests Leukine should be tested in humans as a potential treatment for Alzheimer's disease."

From http://www.sciencedaily.com/releases/2010/08/100822211549.htm —Preceding unsigned comment added by Jo3sampl (talk • contribs) 17:54, 24 August 2010 (UTC)

Update company that owns sargramostim

• What I think should be changed: Additional information on current company who owns sargramostim.

On February 1, 2018, Partner Therapeutics, Inc. acquired the global rights to develop, manufacture, and commercialize Leukine (sargramostim) from Sanofi.

• Why it should be changed: Accuracy.

• References supporting the possible change (format using the "cite" button): Partner Therapeutics (PTx) Acquires Leukine® from Sanofi. February 1, 2018. https://www.prnewswire.com/news-releases/partner-therapeutics-ptx-acquires-leukine-from-sanofi-300591625.html

97.81.195.108 (talk) 19:31, 24 October 2023 (UTC)

 Go ahead: I have reviewed these proposed changes and suggest that you go ahead and make the proposed changes to the page. The proposed text regarding Partner Therapeutics's acquisition of Leukine is acceptable. Please note: Symbols, such as the one for registered (®) are not allowed anywhere in the article. Regards,  Spintendo  02:54, 26 October 2023 (UTC)

Thank you! Added the proposed changes and citation. 97.81.195.108 (talk) 18:25, 7 November 2023 (UTC)

References

Remove paragraph that contains benzyl alcohol formulation. No longer on market.

• What I think should be changed: Delete this paragraph --> "There is a formulation with benzyl alcohol, which is toxic to babies; other formulations should be used. Sargramostim has not been tested in pregnant women but appears to be toxic to fetuses. There is no data as to whether sargramostim is expressed in breast milk.[1]"

• Why it should be changed: This product was removed from the market and no longer appears in the package insert.

• References supporting the possible change (format using the "cite" button): LEUKINE®(sargramostim) for injection, for subcutaneous or intravenous use Prescribing Information. (08/2023). Partner Therapeutics, Inc. https://www.leukine.com/prescribing-information.pdf

97.81.195.108 (talk) 19:36, 24 October 2023 (UTC)

References

 Declined The multiple dose vials that contained bacteriostatic water no longer appear to be manufactured. However, the package insert provided by the COI editor states on page 6 (section 2.7) under Preparation and Administration: Reconstitute with either Sterile Water for Injection, USP (without preservative) or Bacteriostatic Water for Injection, USP (0.9% benzyl alcohol) for intravenous or subcutaneous administration. Because their directions for reconstituting the single dose vial still recommend using either sterile water for injection or bacteriostatic water as the diluent, it can arguably be stated that a benzyl alcohol version remains as "one of their formulations".

Notes

References

Regards,  Spintendo  14:02, 25 October 2023 (UTC)

Thank you. Will not delete paragraph that contains benzyl alcohol formulation. 97.81.195.108 (talk) 18:26, 7 November 2023 (UTC)